Last reviewed · How we verify
Aripiprazole depot
Aripiprazole depot, marketed by UMC Utrecht, is a long-acting injectable antipsychotic with a key composition patent expiring in 2028. The drug's key strength lies in its extended-release formulation, which enhances patient compliance and convenience. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Aripiprazole depot |
|---|---|
| Also known as | Abilify maintena, Abilify |
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder (PHASE1, PHASE2)
- A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia (PHASE1)
- Aripiprazole IM Depot for Chinese Patients With Schizophrenia (PHASE1)
- Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia (PHASE3)
- European Long-acting Antipsychotics in Schizophrenia Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole depot CI brief — competitive landscape report
- Aripiprazole depot updates RSS · CI watch RSS
- UMC Utrecht portfolio CI